New treatments for cancer using human-specific STING activators
Human specific STING agonists for the treatment of cancer
['FUNDING_OTHER'] · STINGINN, LLC · NIH-10759593
This study is looking at a new way to help your immune system fight cancer by using special drugs that can be taken by mouth, making it easier for patients to access treatment and potentially improve how well it works against different types of cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STINGINN, LLC (nih funded) |
| Locations | 1 site (MIAMI, UNITED STATES) |
| Trial ID | NIH-10759593 on ClinicalTrials.gov |
What this research studies
This research investigates the use of human-specific STING agonists to enhance the body's immune response against cancer. By activating the STING pathway, the treatment aims to stimulate the production of immune cells that can target and destroy tumors. The approach focuses on developing oral drug delivery methods to make the treatment more accessible and effective for patients. The research will explore how these agonists can be administered and their potential impact on various types of cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with various types of cancer who are seeking innovative treatment options.
Not a fit: Patients with non-malignant conditions or those who do not have a cancer diagnosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the body's own immune system to fight tumors.
How similar studies have performed: Other research has shown promising results with similar immune-activating approaches, indicating potential for success in this area.
Where this research is happening
MIAMI, UNITED STATES
- STINGINN, LLC — MIAMI, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BARBER, GLEN N — STINGINN, LLC
- Study coordinator: BARBER, GLEN N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Drug, Neoplastic Disease Chemotherapeutic Agents, anti-cancer drug, anticancer agent